×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Anal Cancer
Brielle Urciuoli
The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.
Katie Kosko
A recent study found that socioeconomic status can play a role in survival for patients with anal cancer.
Brielle Urciuoli
Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.
Meeri Kim
More personalized approaches are being developed to treat patients with metastatic disease.
Jason Harris
Despite impressive efficacy for the human papillomavirus (HPV) vaccine reducing the prevalence of high-risk oral HPV infections by 88 percent, many young adults still are not getting the vaccine – sparking concern in the health community.
Jason Harris
The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.
Allie Strickler
From stigma to convenience, there are many reasons why people do not get the HPV vaccine, although it can prevent some types of cancer. Lois Ramondetta, M.D., discusses updated recommendations and hopes for getting more young people vaccinated.
Virginia Powers, PhD
Opdivo may be a promising treatment option for patients with squamous cell carcinoma of the anal canal.
Christina Izzo
A new study has shown that vaccinating adolescent boys may be cost-effective for preventing oropharyngeal cancer, a disease that's projected to become the most common HPV-related cancer by 2020.